390 related articles for article (PubMed ID: 19200416)
1. Breast cancer. Clinical practice guidelines in oncology.
Carlson RW; Allred DC; Anderson BO; Burstein HJ; Carter WB; Edge SB; Erban JK; Farrar WB; Goldstein LJ; Gradishar WJ; Hayes DF; Hudis CA; Jahanzeb M; Kiel K; Ljung BM; Marcom PK; Mayer IA; McCormick B; Nabell LM; Pierce LJ; Reed EC; Smith ML; Somlo G; Theriault RL; Topham NS; Ward JH; Winer EP; Wolff AC;
J Natl Compr Canc Netw; 2009 Feb; 7(2):122-92. PubMed ID: 19200416
[No Abstract] [Full Text] [Related]
2. Multidisciplinary care for patients with breast cancer.
Hulvat MC; Hansen NM; Jeruss JS
Surg Clin North Am; 2009 Feb; 89(1):133-76, ix. PubMed ID: 19186235
[TBL] [Abstract][Full Text] [Related]
3. The prevention, detection, and management of breast cancer.
Houssami N; Cuzick J; Dixon JM
Med J Aust; 2006 Mar; 184(5):230-4. PubMed ID: 16515434
[TBL] [Abstract][Full Text] [Related]
4. National Breast Cancer Audit: overview of invasive breast cancer in New Zealand.
Ooi CW; Campbell ID; Kollias J; de Silva P
N Z Med J; 2012 Aug; 125(1359):7-16. PubMed ID: 22932509
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and Adjuvant Therapies for Breast Cancer.
Apuri S
South Med J; 2017 Oct; 110(10):638-642. PubMed ID: 28973704
[TBL] [Abstract][Full Text] [Related]
6. [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Sayer HG; Höffken K
MMW Fortschr Med; 2003 Jun; 145(24):40-2. PubMed ID: 12866298
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Nagykálnai T
Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
[TBL] [Abstract][Full Text] [Related]
8. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
9. [Slow progress in therapy of breast carcinoma].
Aumiller J
MMW Fortschr Med; 2004 Jan; 146(3-4):4-6, 8, 10. PubMed ID: 15035437
[No Abstract] [Full Text] [Related]
10. Management of breast cancer--Part II.
Turner NC; Jones AL
BMJ; 2008 Jul; 337(7662):a540. PubMed ID: 18621762
[No Abstract] [Full Text] [Related]
11. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen: Dr. Jekyll and Mr. Hyde?
Hayes DF
J Natl Cancer Inst; 2004 Jun; 96(12):895-7. PubMed ID: 15199102
[No Abstract] [Full Text] [Related]
13. Overview of randomized trials of systemic adjuvant therapy.
Ravdin PM
Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
[No Abstract] [Full Text] [Related]
14. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
16. When to start an aromatase inhibitor: now or later?
Doughty JC
J Surg Oncol; 2011 Jun; 103(7):730-8. PubMed ID: 21360530
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
18. Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Higa GM
Drugs; 2006; 66(3):363-4. PubMed ID: 16526828
[No Abstract] [Full Text] [Related]
19. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
